Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GlaxoSmithKline (GSK) Stock Moves -0.8%: What You Should Know
10:00pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
12:49pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
05:21pm, Monday, 27'th Jun 2022 Zacks Investment Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
How Pfizer Plans to Unlock Another Mass-Market Vaccine
02:53pm, Monday, 27'th Jun 2022 The Motley Fool
The company turns its attention to another infectious disease that lacks a vaccine.
Why Sanofi May Be a Frontrunner in Endemic COVID-19
12:09pm, Saturday, 25'th Jun 2022 The Motley Fool
There is a promising outlook for its next generation of vaccines.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
04:30pm, Friday, 24'th Jun 2022 Zacks Investment Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
10:00pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $41.97 in the latest trading session, marking a +0.48% move from the prior day.
Top Analyst Reports for Alphabet, Bank of America & Charles Schwab
06:56pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Bank of America Corporation (BAC), and The Charles Schwab Corporation (SCHW).
GlaxoSmithKline (GSK) Stock Moves -0.74%: What You Should Know
10:00pm, Thursday, 16'th Jun 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $41.64, marking a -0.74% move from the previous day.
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
10:15pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $41.95 in the latest trading session, marking a +1.72% move from the prior day.
COVID-variant booster from Sanofi, GSK shows promising results
09:13pm, Monday, 13'th Jun 2022 MarketWatch
A COVID-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of omicron when given as a booster compared with
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
05:29pm, Monday, 13'th Jun 2022 Zacks Investment Research
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary re
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
01:41pm, Monday, 13'th Jun 2022 Zacks Investment Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the secon
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes
12:45pm, Saturday, 11'th Jun 2022 The Motley Fool
Improving your investing process tends to have high returns.
Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use
12:41pm, Friday, 10'th Jun 2022 Zacks Investment Research
European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.
